Back

Anti-Apolipoprotein A-1 IgG, incident cardiovascular events and lipid paradox in rheumatoid arthritis.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: HIV and cardiovascular disease (1) Autoimmune/Chronic Inflammatory Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Nicolas Vuilleumier

University hospitals of Geneva, Geneva (Switzerland)

8 More presentations in this session

Presentation thumbnail
Effect of interleukin 1b inhibition with canakinumab on inflammation and viral persistence in people with human immunodeficiency virus
Assistant Professor M. Durstenfeld (Los Angeles, US)
Abstract Slides Video
Presentation thumbnail
Large-scale proteomic profiling reveals characteristic HIV-specific druggable protein signatures associated with incident heart failure
Doctor S. Shakil (Los Angeles, US)
Abstract Slides Video
Presentation thumbnail
Influence of disturbed blood flow on endothelial function in people living with HIV
Doctor A. Preveden (Sremska Kamenica, RS)
Abstract Slides Video
Presentation thumbnail
Impaired retinal micro-vascular function in patients with a systemic sclerosis
Ms N. Laptseva (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Reduction of aortic stiffness in newly diagnosed persons with HIV-infection: modifiable vascular dysfunction after antiretroviral therapy?
Doctor P. Robbertse (Cape Town, ZA)
Abstract Slides Video

Access the full session

Session thumbnail
HIV and cardiovascular disease (1)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Prognostic significance of plasma molecular lipid species in coronary artery disease patients: A prospective cohort study
thumbnail
Congress Presentation
Angiotensin-II receptor type 1 and endothelin-1 receptor type A agonistic autoantibodies in patients with STEMI: new kids on the block
thumbnail
Congress Presentation
Predictors of adverse cardiac events in a large cohort of patients with antiphospholipid syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources